Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

NCT04774536 is registered in ClinicalTrials.gov with Mark Walters, MD as lead sponsor.

NCT NCT04774536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04774536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
Lead sponsor
Mark Walters, MD
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 22, 2025
Completion date
March 1, 2030
Enrollment
9 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease